Overview
Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
Status:
Recruiting
Recruiting
Trial end date:
2023-04-23
2023-04-23
Target enrollment:
0
0
Participant gender:
All
All
Summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shenzhen People's Hospital
Criteria
Inclusion Criteria:- New diagnosis ACS patient by serum biomarker and coronary arteriography.
Exclusion Criteria:
- Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea
cancer